Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

3 things you should know about advancing mCRPC care: Targeted sequencing, epigenetics, and emerging strategies.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • نبذة مختصرة :
      The article discusses three things that physicians should know about advancing metastatic castration-resistant prostate cancer (mCRPC) care. Topics discussed include the significance of treatment sequencing and personalization in mCRPC management, the role of Enhancer of Zeste Homolog 2 (EZH2) as a promising epigenetic target in neuroendocrine prostate cancer, and the expansion of therapy options beyond androgen receptor pathway inhibitors and poly (ADP-ribose) polymerase inhibitors.